Canada's National Research Council-Industrial Research Assistance Program has awarded VBI Vaccines up to CA$350,000 ($265,000) to apply VBI's viruslike particle technology in the development of an RSV vaccine, the company announced on Tuesday.
Startup Cofactor Genomics is getting in on the consumer testing craze, developing an innovative RNA-based diagnostic to cash in on a rapidly growing market and challenge business models laid out by rivals.
Researchers at the University of California are developing a novel wireless communication technique, dubbed magnetic field human body communication.
Bristol Myers-Squibb, a leader among companies at work in immuno-oncology, is pressing for wider use of its lead treatment with new data showing the injected drug could succeed as part of a first-line treatment in lung cancer.
The Johns Hopkins University and Luminox Health, a digital health startup hub based in Israel, have signed a multi-year deal to work together to co-develop new digital health technology products. The pair expect to be able to enhance funding access and accelerate development for the resulting companies.
Scientists at NASA are developing a new tool that could produce 3-D images from inside the brain, allowing surgeons to see tissue in greater detail while eliminating barriers typically associated with minimally invasive brain surgery.
Swiss drugmaker Novartis has been on a med tech roll this past year, forging ahead with multiple projects to gain ground in the industry. And at least one of those initiatives, a "smart" contact lens that it's developing with tech titan Google, is already starting to bear fruit.
A team of researchers at Columbia University has developed a method of drug delivery to the lungs that could lead to more efficient dosing for many kinds of lung diseases using microvolume liquid concentrations. By delivering drugs directly to the disease site, treatment can be relegated to the necessary areas without causing dangerous side effects in other nearby organs.
Chronic pain giant Purdue Pharma signed a deal worth as much as $213 million to get its hands on a VM Pharma treatment that could widen the company's portfolio beyond traditional opioid drugs.
Long-troubled drug developer Geron is touting what it calls "unprecedented" early results for its lead cancer drug, sending the biotech's share price up as it moves forward with partner Johnson & Johnson.